Aura Renewable Acquisiti... Share Discussion Threads

[wiganer] 18/7/2006 13:10

and less healthy- at least it's not a boring flatline share

[n_w_b] 14/7/2006 09:05

Piper Jaffray's latest research note, following the results.

"We believe that the potential of Ardana's product pipeline is under-appreciated by the equity market: our current DCF valuation of the company (498p), is more than
300% above the current share price."

[wiganer] 11/7/2006 09:39

and healthy again....

[n_w_b] 06/7/2006 16:48

There's a piece in tomorrows IC

ARDANA (ARA)

Ardana may be small, but its products target the huge human reproductive health market, which is worth nearly $26bn in annual sales, and its now aiming to create value for shareholders by selling its products in the UK through its fledgling sales team. This is possible because its customers are a handful of specialist doctors. And, while the only product it currently has on sale is testosterone-replacement drug Striant, Ardana has the potential to launch a product every year for the next five years.

Erectile dysfunction drug Invicorp is expected to launch this year or early 2007, and chief executive Maureen Lindsay is already in discussions to buy in a new product to sell through the companies sales force. Ardana is also in licensing negotiations for prostate cancer drug Teverelix, which could be a blockbuster. Teverelix is being developed to treat benign prostatic hyperplasia and endometriosis too. Ms Lindsay is now considering possible acquisitions in the US, which could accelerate the companies expansion there.

IC View:
With the iminent launch of Invicorp and the possibility of a licensing deal for Teverelix soon, the shares remain a buy.

[n_w_b] 03/7/2006 17:44

Preliminary Results Presentation now available:


Anticipated Newsflow

Teverelix LA and other collaborations ongoing
Open IND Prostate Cancer/BPH H1 2006
Invicorp™ mutual recognition H1 2006
Results from PII trial of Terbutaline H2 2006
Further Testosterone Cream data H2 2006
Start PIII trial of Testosterone Cream H2 2006
Launch Invicorp™ H2 2006
Teverelix data – Endometriosis H2 2006
Teverelix data – BPH H2 2006
Teverelix data – Prostate Cancer H1 2007
PIII data and regulatory submission of Testosterone Cream H1 2007

Target Launch Dates

�� 2006/7
Striant
Invicorp
Additional marketed product ????

�� 2008 Testosterone Cream

�� 2009 Teverelix Prostate Cancer

�� 2010 Teverelix BPH

�� 2012 tbc
Teverelix Endometriosis
Oral GHS

Summary

�� Dynamic reproductive health company
�� Actively seeking to build critical mass
�� Strong clinical development pipeline
�� Potentially one product launch per year for next five years
�� At least one potential blockbuster
�� Significant deal flow expected
�� Extensive short-term newsflow

[n_w_b] 02/7/2006 20:31

With a number of "well known" pharmas looking at doing a deal, this will result in a higher deal or could end up with a pharma just making an offer for the group. I'd prefer to stay independent and reap the rewards in 3-5 yrs time, instead of a quick buck now.

[serdka] 02/7/2006 00:42

This group of professionals is waiting to inform interested investors of undervalued stocks positioned to increase. Their service is FREE and without any obligation. You have nothing to lose by registering, and everything to Gain! You receive an email alert ONLY when they have identified a worthy selection. The rest is up to you!

[n_w_b] 01/7/2006 23:14

From Fridays FT

Ardana Sets sights on US M&A

Ardana, the maker of reproductive health products, has outlined plans for expansion into the US through acquisition.

Maureen Lindsay, chief executive, said "we expect to accelerate our growth through M&A. We would be looking at companies that are a similar size to us in the first instance."

Ardana also reported that a number of "well known" pharmaceutical groups had expressed interest in licensing Teverelix, its treatment for prostate cancer, which some analysts believe could be capable of delivering $1bn(£550m) of sales a year.

In the year to March 31, Ardana reported slightly higher pre-tax losses of £8.8m(£8.5m) as research and development costs increased from £3.98m to £6.4m. sales more than tripled to £490,000 (£135,000) due to revenue from the groups oral treatment for men with low testosterone levels. Losses per share were 14.7p (20.7p).

EDIT: In a seperate article from the analysts/press meeting, Ardana stated that they wanted a US acquisition of a company with an existing sales force, to sell Testo cream in the US instead of finder a partner in that teritory, therefore retaining more value. They expected to get a significant market share of the estimated $500m US annual sales. They did intend to go into the US market in the long term, but they wanted to bring it forward and "build critical mass" with the launch of Testo cream in early 2008.

This is very good news and could leap us up into the big league.

[n_w_b] 01/7/2006 23:00

From this weeks IC, Page 26.

Small but very profitable
Piper Terrett reports on the small pharmaceutical companies developing niche treatments for which they can charge a premium

Ardana
Scottish biotech Ardana was one of the few biotech companies to float on the main market in 2005. It focuses on developing drugs for human reproductive health. And as this is a huge and fast-growing market, worth $24bn (£12.8bn) in global sales each year, Ardana is initially targeting a handful of niche disease areas while it builds up its sales and marketing team. As with Vernalis's deal with Endo, the strategy is to seek co-marketing deals with partners, ensuring that it retails more value.

Striant, the company's testosterone replacement therapy, is already on the market, albeit with relatively modest sales. Ardana sells the product itself in the UK direct toa network of specialist doctors, and through distributors in Germany and Scandinavia. The company also has Invicorp, its injectable drug for erectile dysfunction, which is expected to reach the market later this year. Overall, the erectile dysfunction market is worth billions of dollars, but the drug will serve a niche market worth $83m in annual sales for patients unable to take Viagra due to heart problems.

In addition, Ardana's testosterone cream for male hypogonadism, targets a market worth $600m in annual sales, and should launch in late 2007. The biotech even has a potential blockbuster in its portfolio in the shape of Teverelix, a treatment for prostate enlargement, endometriosis and prostate cancer.

IC View: The sshares are down on our buy tip at 129p(19 May 2006). But with the possibility of a deal for Teverelix and plenty of news flow to come, they remain a buy.

[fickena] 30/6/2006 07:55

Ardana stands up to the challenge despite losses

MARK SMITH, Deputy Business Editor June 30 2006

Ardana Bioscience, a small-cap Scottish pharmaceutical firm focused on human reproductive health, yesterday reported slightly wider annual losses – but it said it was set to launch its treatment for erectile dysfunction during the second half of the year.

Pre-tax losses for the 12 months to end of March came in at £8.8m, compared with pre-losses of £8.5m in the same period last year.
Revenues climbed to £490,000 from £135,000, after the Edinburgh-based pharmaceutical developer introduced its first product, Striant, an oral treatment for hypogonadism.
However, costs climbed £1.4m to £10.5m – although it ended the 12-month period £19.1m in cash.

In its statement yesterday to the London Stock Exchange, the company said it was "very pleased with the progress across our product portfolio and are highly encouraged by the feedback we have received from the FDA" for Teverelix in the treatment of both prostate cancer and benign prostatic hyperplasa, an enlarged prostate condition common in men over the age of 50.
Ardana also said that Invicorp, its injectable treatment for erectile dysfunction, was "proceeding toward an anticipated launch in the second half of 2006".

The company also said it was pleased with feedback from US Food and Drug Administration for its Testosterone Cream, a gel treatment for hypogonadism, a condition in which men fail to produce sufficient levels of testosterone.
"The clinical development and launch of Teverelix for prostate cancer is on track according to our original schedule in this multi-billion dollar market, and the opportunity to bring forward the launch date for BPH is very exciting for ourselves and potential partners," Ardana added.
It also said there were a number of commercialisa-
tion options for Teverelix, which it wanted more time to consider. Agreements will be in place before Phase III trials commence, the group reiterated.
Shares in Ardana, which floated at 128p in March last year, yesterday closed down 1p at 121p, giving the group a market value of £70.2m.

[wiganer] 14/6/2006 13:01

Chart looking less healthy now....

[n_w_b] 06/6/2006 09:41

New company presentation posted on the Website today:

Newsflow expected:

Results from PII trial of Terbutaline - H1 2006
Teverelix LA and other collaborations - H1 2006
Open IND Prostate Cancer/BPH - H1 2006
InvicorpTM mutual recognition - H1 2006
Launch InvicorpTM - H2 2006
Teverelix data – BPH - H2 2006
Teverelix data – Prostate Cancer - H2 2006
PIII data and regulatory submission of Testo Cream - H2 2006
Start PIII trial of Testo Cream - H2 2006




3 weeks left until the end of the H1 and the full year results. Should be a lot of news flow as this is a recent presentation.

[n_w_b] 28/5/2006 10:42

Fri 26 May 2006
Safe ports can be found as market storm rages
DREW JOHNSTONE

"Another Scottish business winning City plaudits is Ardana, an early-stage drugs developer which some smart money believes has the potential to come up with a global blockbusting drug to fight prostate problems and other diseases some time in the future.

Losses are expected for the next few years but the upside has sparked the interest of some analysts who think the shares are well worth buying now.
"

[fickena] 26/5/2006 10:42

Interesting trading today, with a couple of large trades going through.

[entj] 19/5/2006 14:04

TO ALL ARA HOLDERS -
Time for some well-deserved publicity for this lovely little company.
Let's all do our bit by recommending to at least 5 friends this weekend!

[entj] 19/5/2006 13:25

lovely - thanks!

[n_w_b] 19/5/2006 12:30

Just bought a copy.

Mostly talking about products and how they are retaining value by creating there own sales teams. Also anaylsts 3.30 share price target.

However they state that a licensing deal was due for our main product(Teverelix)
in the first half of the year may well be delayed, due to a number of new partners entering negotiations late in the day. LOVELY!

Bull points

Products targeting $24bn reproductive health market.

Most exiciting product, Teverelix, a possible blockbuster.

Tevelerix licensing deal this year.

Own sales team in the UK helps keep value.


Bear points

Won't make profits for some years.

May need to raise more capital



My comments:
The CEO has already said that they are well funded for all current development(£24m cash/investments that can be converted into cash at anytime). Alsothey are going to create a European sales tem in time for the launch of Teverelix.

[entj] 19/5/2006 09:10

thanks, n_w_b.
I'm not a great follower of IC myself but I believe most of its readers digest the contents over the weekend and act on Monday.
Can you shed any light on the reasons given for the tip?
TIA

[fickena] 19/5/2006 08:57

Looks like the MMs are the only people who read it!

[n_w_b] 19/5/2006 07:36

One of the main Tips in the IC today.

[entj] 11/5/2006 13:36

Don't worry, fickena, that's just the first step!
The thing I like most about this company is its lack of hype in the face of ENORMOUS possibilities.

[fickena] 11/5/2006 08:17

Doesn't matter how many times I read it, it both upsets me and make me excited a the same time!

"Analysts have target prices for the shares in a 285-330p range, which is a
massive leap from their current 128p level."

[n_w_b] 11/5/2006 08:11

Thanks Adam.

[fickena] 11/5/2006 08:09

Edinburgh-based biotech Ardana (ARA) joined the main market last March and since then its pipeline drugs have made good progress. Its leadproduct is its Teverelix compound, which is currently in Phase II trials for benign prostatic hyperplasia (BHP) and prostate cancer and in Phase I trials for endometriosis.

The company is on the lookout for a licensing
partner to take it through Phase III studies and is
expected to secure a deal this year. It could license
the product for the various indications separately
or it could find individual partners for each product.
Either way, when the deal comes it should be a
huge catalyst for the company's share price.

The
market for BHP is worth around $500 million a year
in the US while the market for prostate cancer is
around $3 billion world wide. Analysts have target
prices for the shares in a 285-330p range, which is a
massive leap from their current 128p level.
■

Shares says: Phosphagenics and Ark
should both see their shares rise on the
back of good news this year, but the size of
the markets for the products being
developed by Alizyme, Plethora and Ardana
means that shares in these companies
could really rocket once licensing deals are
announced.